Lobbying

Elusys Therapeutics's latest lobbying report covers Q2 2026, at $20K. The four quarters Q4 2025–Q3 2026 total $60K. Its first report covers Q4 2024; the issues it reports most are Medical/Disease Research/Clinical Labs.

Elusys Therapeutics

Latest quarter
No record
Q3 2026 · 0 reports
Last 12 months
$60K
Last 4 quarters
vs last quarter
−100.0%
Q3 2026 against the quarter before
First report
Q4 2024
The first quarter a report named it

Lobbying by quarter

Elusys Therapeutics lobbying by quarter
Elusys Therapeutics lobbying by quarter
QuarterAmountReports
Q4 2024$20K1
Q1 2025$20K1
Q2 2025$20K1
Q3 2025$20K1
Q4 2025$20K1
Q1 2026$20K1
Q2 2026$20K1
Q3 2026$00

By issue

  • Medical research and clinical labs$140K · 7 reports

An issue's amount splits each report's amount equally over the issues the report lists.

Who was lobbied

  • HOUSE OF REPRESENTATIVES7 reports
  • SENATE7 reports

Firms it paid

Firm
The Conafay Group$140K7 quarters

Former officials lobbying for it

Former position
BRYAN SHUYChief of Staff Rep. Harris; Asst. to Rep. Harris, HouseCmteon Approps; Dep. Asst. Sec and Chief of StaffHHS/Asst.Secretary for Preparedness and Response (ASPR)Q2 2026
DARIN L GARDNERLegislative Correspondent Senator Tim Hutchinson;ResearchAssistant Senate HELP Committee; Chief ofStaffCongresswoman Kay GrangerQ2 2026
JOSH NARROWIntern to Senator CaseyQ2 2026

Lobbying reports

Filed by
07/20for Q2The Conafay Group$20K
04/20for Q1The Conafay Group$20K
01/20for Q4 2025The Conafay Group$20K
25/10/17for Q3 2025The Conafay Group$20K
25/07/18for Q2 2025The Conafay Group$20K
25/04/18for Q1 2025The Conafay Group$20K
25/01/17for Q4 2024The Conafay Group$20K
24/10/16for Q4 2024The Conafay GroupUnder $5,000